This map shows the geographic impact of K A Fleming's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K A Fleming with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K A Fleming more than expected).
This network shows the impact of papers produced by K A Fleming. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K A Fleming. The network helps show where K A Fleming may publish in the future.
Co-authorship network of co-authors of K A Fleming
This figure shows the co-authorship network connecting the top 25 collaborators of K A Fleming.
A scholar is included among the top collaborators of K A Fleming based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with K A Fleming. K A Fleming is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Kohli, Mikashmi, Melanie Wilson, & K A Fleming. (2024). Global alliance for diagnostics. Clinica Chimica Acta. 558. 118553–118553.
Mitchell, S.A., et al.. (1998). Role of interleukin-10 in the pathogenesis of primary sclerosing cholangitis and primary biliary cirrhosis?. Gut. 43. 153–153.1 indexed citations
7.
Healey, Christopher, et al.. (1998). Genetic variation in Immune epitopes in core and envelope regions of hepatitis C virus. UCL Discovery (University College London).2 indexed citations
8.
Mitchell, S.A., et al.. (1997). Cytokine profiles in primary sclerosing cholangitis (PSC) and autoimmune liver diseases: Comparing expression in the periphery and the liver.. Hepatology. 26. 400–400.1 indexed citations
9.
Mitchell, S.A., et al.. (1997). Decreased interleukin-10 mRNA expression in primary sclerosing cholangitis and primary biliary cirrhosis: A role for IL10 in the pathogenesis?. Hepatology. 26. 1253–1253.2 indexed citations
10.
Mitchell, S.A., et al.. (1997). High dose ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis (PSC): Results after two years of a randomised double-blind, placebo-controlled trial.. Gastroenterology. 112.20 indexed citations
11.
Fleming, K A, et al.. (1996). Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.. PubMed. 43(1). 67–5.18 indexed citations
Mehal, Wajahat Z., et al.. (1993). HLA DRW52A AND DW2 ARE NOT ASSOCIATED WITH THE DEVELOPMENT OF ANTI NEUTROPHIL ANTIBODY TYPE1 (ANCA1) IN ULCERATIVE-COLITIS (UC). Gastroenterology. 104.3 indexed citations
14.
Mehal, Wajahat Z., et al.. (1993). IMMUNOGENETIC FACTORS IN THE CLINICAL COURSE OF PRIMARY SCLEROSING CHOLANGITIS (PSC). Gastroenterology. 104. 953.1 indexed citations
15.
Lo, Sing Kai, Roger W. Chapman, James Dooley, & K A Fleming. (1993). ABERRANT HLA-DR ANTIGEN EXPRESSION BY BILE-DUCT EPITHELIUM IN PRIMARY SCLEROSING CHOLANGITIS IS DOWN-REGULATED BY URSODEOXYCHOLIC ACID. Gastroenterology. 104.3 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.